Inhaled nitric oxide in neonates with persistent pulmonary hypertension

Lancet. 2001 Jan 13;357(9250):118-20. doi: 10.1016/S0140-6736(00)03548-0.

Abstract

To investigate the oxygenation and haemodynamic dose response to inhaled nitric oxide in neonates with persistent pulmonary hypertension (PPHN), we gave seven neonates nitric oxide and measured directly pulmonary arterial pressure. Inhaled nitric oxide produced peak improvement in oxygenation at 5 parts per million (ppm) whereas peak improvement in the pulmonary-to-systemic arterial pressure ratio did not occur until a nitric oxide dose of 20 ppm, which suggests that an Initial dose of 20 ppm is optimum for the treatment of PPHN.

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Inhalation
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Infant, Newborn
  • Nitric Oxide / administration & dosage*
  • Vasodilator Agents / administration & dosage*

Substances

  • Vasodilator Agents
  • Nitric Oxide